Stockscreener 앱 받기
8.94
3.00%
0.26
전일 마감가:
$8.68
열려 있는:
$8.635
하루 거래량:
2,063
Relative Volume:
0.01
시가총액:
$9.57M
수익:
-
순이익/손실:
$-57.11M
주가수익비율:
-0.596
EPS:
-15
순현금흐름:
$-34.82M
1주 성능:
-5.99%
1개월 성능:
-11.75%
6개월 성능:
-55.96%
1년 성능:
-89.26%
1일 변동 폭
$8.635
$8.9401
1주일 범위
$8.45
$9.72
52주 변동 폭
$6.50
$83.20
아폴로믹스 Stock (APLM) Company Profile
APLM을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
APLM
Apollomics Inc
|
8.9401 | 9.57M | 0 | -57.11M | -34.82M | -15.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
440.04 | 113.70B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
682.05 | 75.52B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
663.04 | 39.78B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
275.84 | 35.34B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
121.09 | 29.05B | 3.30B | -501.07M | 1.03B | -2.1146 |
아폴로믹스 주식(APLM)의 최신 뉴스
Apollomics, Inc. (NASDAQ:APLMW) Sees Significant Decrease in Short Interest - Defense World
Apollomics phase 3 trial in China shows no benefit - Investing.com India
Biotech fails trials for its leukemia drug - Silicon Valley Business Journal
Apollomics Shares Down in Premarket After Leukemia Drug Misses Phase-3 Targets - MarketWatch
Apollomics Announces Top-line Results for Phase 3 Bridging - GlobeNewswire
Apollomics' Cancer Drug Disappoints in Phase 3 Trial with Lower Survival Rates, Program Terminated - StockTitan
Apollomics Meets Nasdaq Compliance On Bid Price Requirement - Nasdaq
APLM Stock Hits 52-Week Low at $7.51 Amid Market Challenges - Investing.com Australia
APLM Stock Hits 52-Week Low at $7.51 Amid Market Challenges By Investing.com - Investing.com South Africa
Apollomics Regains Compliance with Nasdaq’s Minimum Bid Price Requirement - GlobeNewswire
Apollomics Secures Nasdaq Listing Status After Meeting Crucial Price Requirements - StockTitan
When the Price of (APLM) Talks, People Listen - Stock Traders Daily
Apollomics Inc trading halted, news pending - MSN
Apollomics, Inc. Appoints Matthew Plunkett as Chief Financial Officer - Marketscreener.com
APLM Stock Plummets to 52-Week Low, Hits $8.01 Amid Market Turbulence - Investing.com India
APLM Stock Plummets to 52-Week Low, Hits $8.01 Amid Market Turbulence By Investing.com - Investing.com South Africa
Apollomics, Inc. Reports Earnings Results for the Half Year Ended June 30, 2023 - Marketscreener.com
Apollomics Shares to Reverse Split on Monday, November 25th (NASDAQ:APLM) - Defense World
Apollomics announces 1-for-100 reverse stock split By Investing.com - Investing.com South Africa
Apollomics announces 1-for-100 reverse stock split - Investing.com
Apollomics’ Announces Shareholder Approval and Effective Date for 1-for-100 Reverse Share Split - GlobeNewswire
Apollomics Implements 1-for-100 Reverse Stock Split, Adjusts Warrant Prices | APLM Stock News - StockTitan
Spotlight on Undervalued Nasdaq Stocks: HCWB, CRDL, NIVF, SINT, APLMA Must-Watch This Week! - Marketscreener.com
Stock market today: CareMax(−41.19%), HCW Biologics(+209.06%) among the most volatile stocks in early trading - Business Upturn
Why Tesla Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket - Benzinga
Apollomics, Inc. (NASDAQ:APLM) Sees Significant Drop in Short Interest - Defense World
Apollomics Inc (APLM): Major Improvements, Need To Be Considered - Stocks Register
Biotech Sees Massive Buying Pressure Following Phase 2 Preliminary Data - MSN
Apollomics, Inc. (NASDAQ:APLM) Short Interest Up 32.7% in October - Defense World
Qorvo, Inc. (NASDAQ:QRVO) Given Consensus Rating of “Hold” by Analysts - Defense World
Metastatic Colorectal Cancer Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Daiichi Sankyo Company, Mirati Therapeutics, Apollomics - Barchart
Investor’s Delight: Apollomics Inc (APLM) Closes Weak at 0.14, Down -3.53 - The Dwinnex
Should investors be concerned about APLM’s high price-to-sales ratio? - US Post News
Market Highlights: Apollomics Inc (APLM) Ends on a High Note at 0.16 - The Dwinnex
Market cap of Apollomics Inc [APLM] reaches 17.91M – now what? - The DBT News
Was anything positive for Apollomics Inc (APLM) stock last session? - US Post News
Apollomics Inc (APLM) Stock: Uncovering 52-Week Market Trends - The InvestChronicle
It would be worthwhile to take a closer look at Apollomics Inc (APLM) - US Post News
Investor’s Toolkit: Key Ratios for Assessing Apollomics Inc (APLM)’s Performance - The Dwinnex
Apnimed Announces Early Completion of Enrollment in Phase 3 SynAIRgy Study of AD109, the First Potential Oral Treatment Addressing the Neuromuscular Cause of Obstructive Sleep Apnea - PR Newswire
Apollomics Inc (APLM) Stock: A Year of Highs and Lows in the Market - The InvestChronicle
American Century Companies Inc. Purchases 121,764 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) - Defense World
Texas Permanent School Fund Corp Boosts Stock Position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) - Defense World
Defence company Apollo Micro Systems shortlisted by DRDO for PRACHAND order - ET Now
Apollo Micro System shares in focus after order win worth Rs 5.72 crore | Details here - India.com
Collaborative platform Ampollo aims to open up new revenue streams for music industry - Music Week
This defence company is shortlisted for ToT of PRACHAND Munition Hardware and bags order worth Rs 5.72 crore from Reliable Technosystems India Pvt Ltd - Dalal Street Investment Journal
Analyzing APO’s current quarter earnings projections - US Post News
Apollo Micro Systems shortlisted by DRDO for PRACHAND order - CNBCTV18
Arizona State Retirement System Purchases 410 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) - Defense World
AnaptysBio chief legal officer sells over $490k in company stock - Investing.com
아폴로믹스 (APLM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.45%
5.38%
자본화:
|
볼륨(24시간):